Abstract
Objective: Immune checkpoint inhibitor therapy is approved for platinum-refractory cervical cancer, which yields a response rate (PR) of 12% and stable disease (SD) of 18% in the Keynote 158 phase II study. We hypothesized that the response rate in patients with platinum-sensitive disease may be higher, and aimed at analyzing individual characteristics associated with response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
